Regulation of dendritic spines is an important component of synaptic function and plasticity whereas dendritic spine dysregulation is related to several psychiatric and neurological diseases. In the present study, we tested the hypothesis that serotonin (5-HT)2A/2C receptor-induced Rho family transamidation and activation regulates dendritic spine morphology and that activation of multiple types of receptors can induce transglutaminase (TGase)-catalyzed transamidation of small G proteins. We previously reported a novel 5-HT2A receptor downstream effector, TGase-catalyzed serotonylation of the small G protein Rac1 in A1A1v cells, a rat embryonic cortical cell line. We now extend these findings to rat primary cortical cultures which develop dendritic spines; stimulation of 5-HT2A/2C receptors increased transamidation of Rac1 and Cdc42, but not RhoA. Inhibition of TGases significantly decreased transamidation and activation of Rac1 and Cdc42, suggesting that transamidation led to their activation. In primary cortical cultures, stimulation of 5-HT2A/2C receptors by 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) caused a transient dendritic spine enlargement, which was blocked by TGase inhibition. Stimulation of both 5-HT2A and 5-HT2C receptors contributed to DOI-induced Rac1 transamidation in primary cortical cultures as demonstrated by selective antagonists. Furthermore, stimulation of muscarinic acetylcholine receptors and NMDA receptors also increased TGase-catalyzed Rac1 activation in SH-SY5Y cells and N2a cells, respectively. Receptor-stimulated TGase-catalyzed transamidation of Rac1 occurs at Q61, a site previously reported to be important in the inactivation of Rac1. These studies demonstrate that TGase-catalyzed transamidation and activation of small G proteins results from stimulation of multiple types of receptors and this novel signaling pathway can regulate dendritic spine morphology and plasticity.
Introduction
In the central nervous system, the majority of the excitatory synapses are composed of postsynaptic terminals located on dendritic spines (Phillips and Pozzo-Miller, 2015) . Changes in size, number and morphology of dendritic spines are tightly coordinated with synaptic function and plasticity, underlying the establishment and remodeling of neuronal circuits, learning and memory, and behavior Kennedy, 2016) .
Notably, malfunction of dendritic spines accompanies a large number of brain disorders, including bipolar disorder, autism spectrum disorder, schizophrenia and Alzheimer's disease, suggesting that dendritic spines can serve as a common target for those complex diseases (Penzes et al., , 2013 Konopaske et al., 2014; Phillips and Pozzo-Miller, 2015) . Understanding the molecular underpinnings of dendritic spine regulation may provide essential insights into the etiologies of those disorders and may reveal new drug targets.
Morphological changes of dendritic spines are driven by actin dynamics, which can be regulated by small G proteins of the Rhofamily. At the synapse, Rac1, Cdc42 and RhoA play a pivotal role in spine formation and morphogenesis, and synaptic plasticity (Martino et al., 2013) . Activation of Rac1 and Cdc42 promotes spine formation, growth and stabilization; conversely, RhoA activation leads to spine pruning. Perturbations in Rho family signaling are implicated in various brain disorders, particularly those associated with cognitive deficits, such as mental retardation, schizophrenia and Alzheimer's diseases (Ba et al., 2013; Bolognin et al., 2014; Datta et al., 2015) .
Numerous studies have demonstrated that the activity of small G proteins including those of the Rho family is regulated by monoaminylation (Muma and Mi, 2015) . Monoaminylation is a posttranslational modification of proteins in which transglutaminases (TGases) catalyze the transamidation of a primary amine molecule such as serotonin (5-HT) or dopamine to a protein-bound glutamine residue (Muma and Mi, 2015) . Serotonylation is a term for the specific transamidation of 5-HT to a protein (Walther et al., 2003) . Stimulation of serotonin 2A (5-HT2A) receptors induces serotonylation of Rac1, resulting in Rac1 activation (Dai et al., 2008 ). An increase in intracellular Caþ2subsequent to receptor stimulation was both necessary and sufficient to stimulate serotonylation and activation of Rac1 (Dai et al., 2011) . Together, these findings lead us to hypothesize that multiple receptor subtypes increase TGasecatalyzed transamidation and activation of small G proteins which can alter dendritic spine morphology.
5-HT2A receptors are widely distributed in most forebrain regions. Disrupted function of 5-HT2A receptors has been identified in various neurological and psychiatric disorders such as schizophrenia, Alzheimer's disease (Feh er et al., 2013) , autism, depression and anxiety (Gray and Roth, 2007; Berg et al., 2008; Herv as et al., 2014) . 5-HT2A receptors are also the target for several antidepressants, anxiolytics, atypical antipsychotics and hallucinogens (Gonz alez-Maeso et al., 2007; Mestre et al., 2013; Amodeo et al., 2014) . 5-HT2A receptors localize to dendrites, dendritic shafts, and dendritic spines (Cornea-Hebert et al., 2002; Peddie et al., 2008) . Initiation of 5-HT2A receptor expression coincides with the period of synaptogenesis (Roth et al., 1991) . 5-HT2A receptor activation alters dendritic spine area via a kalirin-7 dependent pathway (Jones et al., 2009 ). Stimulation of 5-HT2A receptors also changes the density of specific subtypes of dendritic spines (Yoshida et al., 2011) . Those studies suggest that 5-HT2A receptors play a role in the regulation of dendritic spine architecture and actin cytoskeleton. However, the underlying mechanisms by which the 5-HT2A receptor signaling regulates dendritic spines and the role of serotonylation of Rac1 and possibly other members of the Rho family in the process are not clear.
NMDA receptors can mediate synaptic plasticity such as longterm potentiation (Collingridge et al., 1983) . NMDA receptor activation causes an influx of Ca 2þ and activation of calmodulindependent kinase II. The Ca 2þ influx and activation of calmodulindependent kinase II result in recruitment of AMPA receptors to the synapse and dendritic spine enlargement both of which are determinants of synaptic strength (Matsuzaki et al., 2004) . The Ca 2þ influx is necessary for activation of small G proteins in the dendritic spines and subsequent increase in spine volume (Murakoshi et al., 2011) . We hypothesize that the NMDA receptordependent influx of Ca 2þ increases TGase-catalyzed transamidation and activation of small G proteins. Muscarinic receptor signaling has also been shown to be involved in synaptic plasticity and can produce long-term potentiation (Dennis et al., 2015) , perhaps also by a mechanism involving TGase-catalyzed transamidation and activation of small G proteins.
In the present study, we used rat primary cortical cultures which develop dendritic spines to test whether activation of TGase via stimulation of 5-HT2A/C receptors induces transamidation and activation of Rac1, Cdc42 and RhoA, and whether the transamidation results in changes of dendritic spine architecture. SH-SY5Y and N2A cell lines were used for biochemical studies to examine muscarinic, NMDA and AMPA receptors. Our results indicate that both G protein-coupled and ligand-gated ion channel receptors can stimulate transamidation and activation of Rac1 and that transamidation can regulate dendritic spine size.
Materials and methods

Reagents
1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl (DOI), N-Methyl-D-aspartic acid (NMDA), (S)-a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and (2-hydroxyethyl) trimethylammonium chloride carbamate (carbachol) (SigmaAldrich, St. Louis, MO) and 2-aminoethyl disulfide dihydrochloride (cystamine) (MP Biomedicals, Solon, OH) were dissolved in saline or water and further diluted before application to cell cultures. SB 242084 (Sigma-Aldrich, St. Louis, MO) was dissolved in ethanol (the final concentration of ethanol exposure to cells was 0.1%). MDL100907 was kindly provided by Sanofi Aventis (Bridgewater, NJ) and dissolved in DMSO (the final concentration of DMSO exposure to cells was 0.01%).
Cell culture and transfection
A1A1v cells, SH-SY5Y and N2a cells were cultured and transfected as previously described for all of the biochemical experiments (Yu et al., 1990; Dai et al., 2008; Coleman et al., 2013) . In addition, A1A1v cells were transfected with either of the following mammalian expression plasmid constructs: TGase1 (TGM1, clone ID: OHu23436, Genscript, NJ, USA) or TGase3 (TGM3, clone ID: OHu31856, Genscript, NJ, USA) with a common pcDNA3.1þ-DYK vector backbone. Before each experiment, cells were maintained for 48 h in Dulbecco's modified Eagle medium (Fisher Scientific, Pittsburgh, PA) containing 10% fetal bovine serum (Atlanta Biologicals, Flowery Branch, GA) treated with charcoal to remove > 99% of endogenous 5-HT (Unsworth and Molinoff, 1992) . Cells used as non-transfected control cells were incubated in charcoal filtered FBS but were otherwise untreated.
Primary cortical culture
Animals were used in accordance with the National Institute for Health Guide for the Care and Use of Laboratory Animals as approved by the University of Kansas Institutional Animal Care and Use Committee. Primary cortical neurons were isolated from E18 Sprague-Dawley rat embryos as described previously with minor modifications (Srivastava et al., 2011; Beaudoin III et al., 2012) . The cortical tissues from feti from each pregnant rat were harvested and the cells from each litter were then pooled. Neurons were plated at a density of 5 Â 10 5 cells/ml on 22 mm diameter round cover glass (Neuvitro Corporation, Vancouver, WA) or at a density of 2.7 Â 10 6 cells/ml on T25 cell culture flasks (Fisher Scientific, Lenexa, KS) coated with poly-L-lysine (Sigma-Aldrich, St. Louis, MO). At 21 days in vitro (DIV), cultures were randomly chosen for treatment with 3 mM DOI or vehicle and in some experiments pretreatment with either 1 mM cystamine or a selective 5-HT receptor antagonist or vehicle.
Immunocytochemistry
Primary neurons were double-labeled with Alexa Fluor ® 568
Phalloidin (Life Technologies, Grand Island, NY) for labeling F-actin, antibodies against microtubule-associated protein 2 (Map2) clone HM-2 (Sigma-Aldrich, St. Louis, MO) for labeling dendrites, antibodies against 5-HT2A receptors (Singh et al., 2007) , and antibodies against PSD95 (6G6-1C9) (Life Technologies, Grand Island, NY 
Quantitative analysis of spine morphology
Neurons were visualized with an Olympus/3I Spinning Disk confocal microscope using a 100Â TIRF oil immersion objective. Zseries of twenty to thirty images were taken at 0.2 mm intervals, with 1024 Â 1024 or 500 Â 500 pixel resolution. Three-dimensional maximum projection reconstructions and deconvolution were performed using Slidebook 5.5 or 6 (Intelligent Imaging Innovations, Inc). To examine the morphology of dendritic spines, dendrites (labeled with MAP2) and dendritic spines were first chosen based on expression of 5-HT2A receptors, and then phalloidin labeling of F-actin was used for measurements of individual spines. Dendrites and individual spines on dendrites were traced, and dendritic area was measured using CellProfiler (Broad Institute, Cambridge, MA). Length of dendrites was measured using Image J (National Institutes of Health, Bethesda, Maryland). Spine density was measured using Neuron Studio (Icahn School of Medicine at Mount Sinai, New York, NY). Spines on one or two primary dendrites of each neuron, and 5e10 neurons for each condition were analyzed from three separate experiments. The length of dendrites used for the analysis was at least 30 mm. The experimenter was blinded to the treatment group during dendritic spine measurements. To reduce TGase2 protein expression, siRNA duplex targeting the coding sequence of rat TGase2 mRNA was used as previously reported with minor modification (Dai et al., 2008) . The target sequence 5-AAGAGCGAGATGATCTGGAAT-3 was synthesized by QIAGEN (Germantown, MD). At 19 DIV, primary neurons were transfected with siRNA at a final concentration of 90 nM using Lipofectamine 3000 without P3000 reagent according to the manufacture's instruction. 72 h after transfection, cells were treated with DOI or saline. Cells incubated with Lipofectamine 3000 alone were used as a mock-transfected control.
Site-directed mutagenesis
Immunoblot
Protein samples were separated on 12% or 14% SDSpolyacrylamide gels as previously described (Dai et al., 2008) . The primary antibodies used are as follows: mouse anti-Rac1 antibody, clone 23A8, 1:700 (Millipore Corporation, Billerica, MA); mouse anti-Cdc42 antibody, clone 44, 1:500 (BD Biosciences, BD Biosciences); rat anti-flag antibody, 1:500 (Agilent Technologies, USA); mouse anti-TGase1 antibody (E-6),1:200 (Santa Cruz Biotechnology, Inc, USA), rabbit anti-5-HT2A receptor antibody, 1:20,000 (Singh et al., 2007) , mouse anti-5-HT2C receptor antibody (D-12), 1:200 (Santa Cruz Biotechnology, Inc, Dallas, TX), mouse anti-actin antibody, 1:50,000 (MP Biomedicals, Solon, OH). Goat-anti-mouse or goat-anti-rabbit secondary antibodies conjugated to HRP (Jackson ImmunoResearch, West Grove, PA) were used to bind to the primary antibodies and were detected using enhanced chemiluminescence western blotting detection reagents (Amersham Biosciences, Piscataway, NJ). The signals were detected using ChemiDoc™ XRS þ System (Bio-Rad, Hercules, CA) and quantified by calculating the integrated optical density (IOD) of each protein band using Image Lab™ Software (Bio-Rad, Hercules, CA).
Immunoprecipitation of TGase-Modified protein
Immunoprecipitation of TGase-modified protein was performed as described previously with minor modifications (Dai et al., 2008) . Briefly, cells were harvested and lysed and the protein concentration in the lysates was determined using a BCA Protein Assay kit (Pierce, Rockford, IL). 200 mg and 600 mg protein were used for detecting Rac1 and Cdc42 transamidation respectively. Isolation of proteins containing TGase-catalyzed bonds was performed by immunoprecipitation using 81D4 mAb (mouse IgM) prebound to Sepharose beads (Covalab, Lyon, France) and the protocol developed by Covalab as described previously (Dai et al., 2008) . The 81D4 antibody is selective for the Nε-(g-glutamyl) lysine isopeptide, which is the TGase-catalyzed bond between a protein-bound lysine residue and protein-bound glutamine residue (El Alaoui et al., 1991) . Several other potential epitopes similar to the Nε-(g-glutamyl) lysine isopeptide were found not to cross-react with the 81D4 antibody (El Alaoui et al., 1991) , with the exception of transamidation of a peptide bound lysine to serotonin and possibly other small amines (Dai et al., 2008) .
Activity assay for small G proteins
Active Rac1 and Cdc42 bind to PAK1 and can be separated for measurement on immunoblots. The activity of Rac1 and Cdc42 was measured using Glutathione Transferase (GST) -PAK1 bound Sepharose 4B beads as described previously (Dai et al., 2008) . PAK1-bound protein samples were loaded on 14% SDS PAGE and Rac1 or Cdc42 detected on immunoblots as described above.
Statistical analysis
Data are presented as mean ± standard error of the mean (SEM). All data are analyzed by Student's t-test, one, or two-way ANOVA, or Kruskal-Wallis one-way ANOVA on Ranks. Post hoc tests were conducted using Newman-Keuls multiple comparison test, Dunn's method or Tukey's multiple comparison test. Sigmaplot 12 (Systat Software, Inc., San Jose, CA) Origin 8.0 (OriginLab Corporation, Northampton, MA) and GraphPad Prism version 6.02 (GraphPad Software, Inc., La Jolla, CA) were used for statistical analysis.
Results
5-HT2A/2C receptor-stimulated Rac1 activation in primary cortical culture
To determine whether Rac1 activation by 5-HT2A/2C receptor stimulation alters dendritic spine morphology, we used primary cortical neurons from E18 rat pups cultured for DIV21. At this stage, dendritic spines display a relatively mature morphology and form connections with presynaptic partners.
To determine whether Rac1 activity is increased following 5-HT2A/2C receptor stimulation in this primary culture model, we used a PAK1 pull down assay, in which only activated GTP-bound Rac1 can bind to PAK1 (Parrini et al., 2002) . We treated the primary neurons with 3 mM DOI, a 5-HT2A/2C receptor-selective agonist, for 5min, the period previously used to detect Rac1 activation in A1A1v cells (Dai et al., 2008) . As shown in Fig. 1A , the ratio of GTP-bound Rac1 to the total Rac1 is significantly increased by 100% after DOI treatment, indicating that Rac1 becomes activated following DOI treatment in primary cultures as in A1A1v cells.
Next, to determine whether Rac1 transamidation is increased in rat primary culture, we treated the neurons with 3 mM DOI for 15min, the time point at which we observed the most abundant Rac1 transamidation in A1A1v cells (Dai et al., 2008) . The ratio of TGase-modified Rac1 to total Rac1 is significantly increased following DOI treatment (Fig. 1B) , suggesting Rac1 is transamidated after stimulation of 5-HT2A/2C receptors in rat primary cortical cultures.
To exam whether the DOI-stimulated increase of active Rac1 is due to TGase-catalyzed transamidation, we inhibited the activity or expression of TGase by treating the primary neurons with 1 mM cystamine, a TGase inhibitor, or transfecting a siRNA targeting TGase2 into the primary neurons, followed by DOI treatment. We also examined the expression of other TGase proteins to determine the selectivity and possible off-target effects of the siRNA. As shown in Fig. 1C , siRNA transfection resulted in a 45% decrease in TGase2 protein levels accompanied by an 85% increase in TGase1 protein levels. TGase3 was not detected on Western blot using a TGase3 specific antibody (data not shown). Compared with DOI-stimulated mock-transfected cells, cystamine treatment caused a 70% decrease and siRNA transfection caused 40% decrease in TGase-modified Rac1 following DOI treatment, suggesting that 5-HT2A/2C receptormediated Rac1 transamidation is dependent on the activity of TGases (Fig. 1D ). The reduction in DOI-induced Rac1 transamidation caused by cystamine is significantly higher than TGase2 siRNA. We also found that treatment with cystamine and siRNA transfection decreases the amount of DOI-induced Rac1 activation by 56% and 38%, respectively, compared with mock-transfected cells. These results indicate that TGase-catalyzed transamidation is necessary for the increase in Rac1 activity upon 5-HT2A/2C receptor stimulation in rat primary cortical neurons (Fig. 1E ).
TGase 1 and 3 do not activate Rac1 due to 5-HT2A receptorstimulation in A1A1v cells
Since TGase2 siRNA increased expression of TGase1 in rat primary cells, we sought to determine if TGase1 and 3, which are both expressed in brain, are able to catalyze the activation of Rac1. To examine whether the DOI-stimulated increase of active Rac1 can be catalyzed by TGase1 and TGase3, we overexpressed TGase1 and TGase3 constructs in A1A1v cells and treated the cells with 3 mM DOI. In cells transfected with the TGase1 construct, there was a A. DOI increased of the activity of Rac1 in primary cortical neurons. After 5 min of 3 mM DOI treatment, active Rac1 (~21 kDa) was pulled down using GST-PAK1 coupled to glutathione-sepharose beads and measured on immunoblots. Bands at 37 kDa and 27 kDa are non-specific binding to components of the PAK1 pull-down assay as demonstrated by their presence in the negative control lane. The negative control lane was loaded with a sample in which the cell lysate (used in the other samples shown in lanes 1e4) was replaced with lysis buffer but was otherwise treated in an identical manner. The presence of these non-specific bands varied with the batch of sepharose beads. IOD ratio between active Rac1 and total Rac1 was normalized to vehicle-treated control levels. DOI significantly increased activated Rac1 in DOI-treated neurons. Student's t-test indicates * p 0.001, n ¼ 3.
B. DOI increased Rac1 transamidation in primary cortical neurons. Primary cortical neurons were treated with 3 mM DOI, the TGase-modified proteins were immunoprecipitated with 81D4 antibody bound Sepharose beads and detected on immunoblots. Total amount of Rac1 (21 kDa band in all immunoblots) in cell lysates was also detected on immunoblots using an anti-Rac1 antibody. Data are quantified by calculating the IOD of each protein band and the IOD ratio between TGase-modified Rac1 and total Rac1 was normalized to vehicle-treated control levels. Rac1 transamidation was significantly increased in DOI-treated neurons. Student's t-test indicates * p < 0.001, n ¼ 3. C. TGase2 protein levels were significantly reduced 72 h after transfection of primary neurons with 90 nM TGase2-specific siRNA (Student's t-test indicates * p ¼ 0.001, n ¼ 3). The reduction in TGase2 is accompanied by an increase in TGase1 protein levels. Student's t-test indicates * p < 0.05, n ¼ 3. D. Transamidation of Rac1 is reduced by inhibition of TGase activity by cystamine or knockdown of TGase2 by siRNA. Cells were incubated with TGase2-specific siRNA for 72 h or with 1 mM cystamine for 1 h, and then they were treated with 3 mM DOI or vehicle for 15 min, and TGase-modified Rac1 was detected on immunoblots at approximately 21 kDa. The bands at 27 kDa are non-specific binding due to components of the immunoprecipitation assay as demonstrated by the presence of this band in the negative control lane. The negative control lane was loaded with a sample in which the cell lysate was replaced with only lysis buffer but was otherwise treated in an identical manner. Two-way ANOVA analysis of three separate experiments shows significant effects of transfection or pretreatment [F (2,12 G. DOI-induced Rac1 transamidation is mediated by both 5-HT2A and 5-HT2C receptors in rat primary cortical neurons. Vehicle-treated rat primary cortical neurons express 5-HT2A (~45 kDa) and 5-HT2C receptors (~48 kDa) as demonstrated on immunoblots. Cells were treated with MDL 100907, SB24084 or vehicle followed by DOI stimulation. TGase-modified Rac1 was detected on immunoblots. The percent increase in transamidation following treatment with DOI varies between experiments from approximately a 50% increase, as in figure 1B , to a nearly 300% increase in figure 1G . Also note that there was large variability in the data presented in figure 1G in the group treated with vehicle/DOI as indicated by the large error bar. Two-way ANOVA analysis of three separate experiments shows significant effects of pretreatment [F (2,12 significant effect of DOI treatment but no effect of TGase1 transfection on Rac1 activation (Fig. 1F, left) . In cells transfected with the TGase3 construct, there was no effect of either treatment or TGase3 transfection on Rac1 activation (Fig. 1F, right ). An anti-flag antibody was used to detect expression of TGase1 and 3. We further verified expression of TGase1 using a TGase1-specific antibody since only low levels of TGase1 expression were detected using the anti-flag antibody. Overall, our results suggest that neither TGase1 nor TGase3 catalyze Rac1 activation due to 5-HT2A/C receptorstimulation in A1A1v cells.
3.3. DOI-induced Rac1 transamidation is mediated by both 5-HT2A and 5-HT2C receptors in primary cortical neurons DOI is a selective 5-HT2A/2C receptor agonist. We determined whether both 5-HT2A and 5-HT2C receptors are expressed in the primary cortical cultures using western blots and found that both receptors are expressed as shown in Fig. 1G . In order to test whether 5-HT2A or 5-HT2C, or both receptors mediate the DOIstimulated Rac1 transamidation in rat primary cortical cells, we pretreated the rat primary neurons with 3.6 nM MDL100907, a selective 5-HT2A receptor antagonist, 10 nM SB242084, a selective antagonist for the 5-HT2C receptors, or DMSO, for one hour. We then stimulated cells with DOI or saline for 15min and examined Rac1 transamidation as described above. As shown in Fig. 1G , the ratio of TGase-modified Rac1 to total Rac1 is significantly increased following DOI treatment, and both MDL100907 and SB24084 suppressed DOI-induced Rac1 transamidation. These results suggest that both 5-HT2A and 5-HT2C receptors contribute to DOIstimulated Rac1 transamidation mediated by TGases.
Stimulation of 5-HT2A/2C receptors increases activation of Cdc42
We examined TGase-modified Cdc42 in A1A1v cells after treatment with 3 mM DOI for 30min, 1 h, 2 h or 3 h. The Cdc42 transamidation is significantly elevated after 2 h and 3 h of DOI treatment ( Fig. 2A) .
We observed an increase in Cdc42 activity at 5min, 15min and 30min post-DOI treatment in A1A1v cells (data not shown). To further determine the duration of DOI-induced Cdc42 activation, we examined a more extended time-course (0.5, 1, 2, and 3 h) of DOI-treatment in A1A1v cells. As shown in Fig. 2B , the activity of Cdc42 is significantly increased following 30 min, 1 h and 2 h DOI treatment but not 3 h compared with vehicle-treated cells, suggesting that DOI-induced Cdc42 activation lasts up to 2 h with a peak at one hour in A1A1v cells.
We found that pretreatment with cystamine decreases the amount of activated Cdc42 at all three time points, 30 min, 1 h or 3 h, suggesting the DOI-induced Cdc42 activation is due to the TGase-catalyzed transamidation of Cdc42 in A1A1v cells (Fig. 2C) .
Next, we found that Cdc42 is activated and transamidated after DOI treatment for 15 min in primary cortical neurons (Fig. 2D&E) . A significant reduction in TGase-modified Cdc42 by cystamine pretreatment and TGase2 siRNA transfection was shown in Fig. 2D , suggesting 5-HT2A/2C receptor-mediated Cdc42 transamidation is dependent on the activity of TGases in primary culture. Compared to DOI-stimulated mock-transfected cells, cystamine treatment caused an 84% decrease and siRNA transfection caused a 34% decrease in TGase-modified Cdc42 following DOI treatment. As shown in Fig. 2E , DOI-induced increases in the ratio of GTP-bound Cdc42 to the total Cdc42 were attenuated 75% and 54% by pretreatment with 1 mM cystamine and TGase2 siRNA, respectively. These results suggest that DOI-stimulated TGase-catalyzed Cdc42 transamidation leads to Cdc42 activation in rat primary cortical neurons.
RhoA is not transamidated following DOI treatment in primary cortical neurons
We also tested whether RhoA is modified by TGases following DOI treatment. We were not able to detect TGase-catalyzed modification of RhoA in rat primary cortical cells at any of the time points examined, from 15 min up to 24 h (Fig. 2F) . These results suggest that stimulation of 5HT2A/2C receptors does not induce significant levels of TGase-catalyzed RhoA transamidation in rat primary cortical cells.
TGase-catalyzed transamidation of Rac1 occurs at Q61 of Rac1 sequence in neuronal cells
We searched for GTP/Mg 2þ binding sites, and GTPase activating protein (GAP), guanine nucleotide exchange factor (GEF), and guanine nucleotide dissociation inhibitor (GDI) interaction sites in the Rac1 sequence (accession number: NP_008839) using the Conserved Domain Database (available on http://www.ncbi.nlm. nih.gov/Structure/cdd/cdd.shtml) since TGase-catalyzed modifications at these sites would more likely lead to functional changes that would impact Rac1 activity. Four glutamine residues (Q61, Q74, Q141, and Q162) are located in the activity-related domains and were targeted for site-directed mutagenesis. We generated two plasmid constructs containing double mutations, one with a Q61/ 74N and the other with Q141/162N. We transfected wild type (WT) Rac1 and Rac1 mutants into A1A1v cells, and 48 h later stimulated 5-HT2A/2C receptors with DOI treatment. As shown in Fig. 3A , DOI significantly increases TGase-modified WT Rac1. Transamidation of Q61/74N Rac1 was not increased following DOI treatment compared with vehicle-treated control. To determine whether Q61 or Q74 or both are modified by TGase, we generated another two Rac1 mutants bearing a single mutation at Q61 or Q74, and transfected them into A1A1v cells. DOI stimulation significantly increased TGase-modified Q74N Rac1 and WT Rac1, but not Q61N Rac1, suggesting that Q61 is the site that is transamidated following stimulation of 5-HT2A/C receptors (Fig. 3B) . Transfection of Q61N Rac1 resulted in an increase in Rac1 activation independent of DOI stimulation (Fig. 3C) . These results suggest that the Q61N Rac1 mutant is constitutively active.
Stimulation of muscarinic receptors in SH-SY5Y cells causes TGase-dependent Rac1 transamidation and activation
As previously reported, 5-HT2A receptor-induced PLC activation is necessary for TGase-catalyzed Rac1 transamidation, and an increase in intracellular Ca 2þ is sufficient to cause Rac1 transamidation in A1A1v cells (Dai et al., 2011) . Therefore, we hypothesized that other Gaq/11 linked-receptors that activate PLC and increase in intracellular Ca 2þ also result in Rac1 transamidation.
To test this hypothesis, we used a human neuroblastoma cell line SH-SY5Y cells, which express M1, M2 and M3 receptors (Kukkonen et al., 1992) . In this cell line, carbachol treatment can activate muscarinic receptors and induce PLC activation and subsequently an increase in cytosolic Ca 2þ (Wojcikiewicz et al., 1994) . As shown in Fig. 4A , carbachol increases Rac1 activity significantly at 10min but not at 5min. To test whether carbachol-increased Rac1 activity is due to transamidation, we pretreated SH-SY5Y cells with 1 mM cystamine to inhibit TGases and then stimulated muscarinic receptors with carbachol. As shown in Fig. 4B , carbachol increased Rac1 transamidation by 150% in vehicle-pretreated cells. Cystamine reduced the carbachol-stimulated Rac1 transamidation by 78% compared to vehicle-pretreated cells. As shown in Fig. 4C , cystamine also decreased carbachol-induced Rac1 activity by 78% compared to vehicle-pretreated controls. immunoprecipitated with 81D4 antibody bound Sepharose beads and detected on immunoblots using anti-RhoA antibody. Total amount of RhoA (molecular mass~22 kDa) in cell lysates was also detected on western blots using an anti-RhoA antibody. The experiment was repeated three times with similar results. "Neg" indicates 81D4 beads were only incubated with IP buffer but not protein lysate. 
Stimulation of NMDA receptors in N2a cells causes TGasedependent Rac1 activation
Ca 2þ is a co-factor for the enzyme TGase and since an increase in intracellular Ca 2þ was sufficient to increase TGase-catalyzed Rac1 transamidation and activation (Dai et al., 2011) , we reasoned that stimulation of other types of receptors that increase free intracellular Ca 2þ , such as ligand-gated ion channels NMDA and AMPA might also be able to increase TGase-catalyzed activation of Rac1. To test this hypothesis, N2a cells, which express NMDA and AMPA receptors, were stimulated with 50 mM NMDA or 100 mM AMPA for 5 or 15 min. As shown in Fig. 4D , NMDA increased Rac1 activation and pretreatment with the TGase inhibitor cystamine prevented this increase. Stimulation of AMPA receptors did not increase Rac1 activity at 5 and 15 min post-stimulation, time points which previously resulted in activation following stimulation of the Gaq/11 linked receptors.
DOI-induced dendritic spine enlargement is dependent on TGase activity
In our cultured rat primary neurons, phalloidin labeled f-actin in dendritic spines (Fig. 5A ) and MAP2 immunolabeled the dendrites. To test whether stimulation of 5-HT2A receptors influences dendritic spine morphology, we performed a time course study in which primary neurons were treated with 3 mM DOI for up to 60min. The area of dendritic spines increased by DOI treatment at 30min, and recovered to vehicle-treated control levels at 60min (Fig. 5B) . To determine whether TGase-catalyzed transamidation of small G proteins including Rac1 and Cdc42 mediates the effect of DOI on dendritic spine morphology, we inhibited TGase by pretreatment with 1 mM cystamine for 1 h, prior to DOI treatment for 30min. DOI-induced spine enlargement is prevented by cystamine pretreatment (Fig. 5A and C) , suggesting the 5-HT2A and/or 5-HT2C receptor stimulation induced increases in spine area is dependent on TGase activity, likely transamidation of small G proteins Rac1 and Cdc42. Two-way ANOVA test indicates that neither cystamine (1.5 h post-treatment) nor DOI (30 min post-treatment) has a significant effect on dendritic spine density (Fig. 5D ).
Discussion
We previously reported that stimulation of 5-HT2A receptors induced Rac1 transamidation and activation, both of which can be blocked by inhibiting TGase (Dai et al., 2008) . However, as a novel effector and second messenger of the 5-HT2A receptor signaling pathway, the functional impact of Rac1 transamidation in neuronal cells was unknown. Small G proteins of the Rho family are well known regulators of the actin cytoskeleton, neurite outgrowth and dendritic spine formation, morphogenesis and plasticity (Ba et al., 2013; Martino et al., 2013) . Specifically, activation of Rac1 and Cdc42 leads to spine formation and enlargement. Stimulation of 5-HT2A receptors produces a transient increase in dendritic spine size that is dependent on Pak1 activation, a downstream effector of Rac1 and Cdc42 activation (Jones et al., 2009) . Therefore, we hypothesized that the transient spine enlargement caused by stimulation of 5-HT2A receptors is dependent on TGase-catalyzed transamidation of Rac1 and Cdc42. Our time course experiment demonstrated that the area of dendritic spines is significantly increased 30 min after treatment with DOI, consistent with previous results reported by Jones et al. (2009) . Furthermore, the present study demonstrated, for the first time, that regulation of dendritic spines via 5-HT2A/2C receptors is dependent on TGase activation. We found that cystamine is able to inhibit the DOI-induced transient spine enlargement, suggesting that TGase-catalyzed Rac1 and/or Cdc42 transamidation plays a vital role in mediating the regulation of dendritic spines via the 5-HT2A/2C receptor signaling pathway.
In the present study, we first demonstrated that stimulation of 5-HT2A/C receptors causes TGase-mediated transamidation and activation of small G proteins Rac1 and Cdc42 in primary culture as previously shown for Rac1 in A1A1v cells. We used two approaches to suppress TGase activity in primary culture, the competitive TGase inhibitor cystamine and TGase2 siRNA. Cystamine produced a more robust reduction in DOI-induced Rac1 transamidation which correlated with a more robust reduction in Rac1 activity than with TGase2 siRNA. TGase2 siRNA resulted in a 95% reduction of TGases2 protein level in A1A1v cells (Dai et al., 2008) , however, in rat primary cortical culture only a 45% reduction of TGase2 was achieved. As a substrate for TGase, cystamine acts as a competitive inhibitor for all TGase subtypes, while the siRNA only targets TGase2. We found that the TGase2 siRNA also increased TGase1 protein expression in primary cortical culture, which may be a compensatory effect of TGase2 reduction. TGase2 is ubiquitously expressed in neuronal tissues, in contrast to TGase1 and 3 which are differentially expressed in various brain regions (Kim et al., 1999; Zainelli et al., 2005; Wilhelmus et al., 2009 ). TGase3 was not detectable in the primary neuronal cultures by western blots. Neither TGase1 nor TGase3 over-expression increased activation of Rac1 following DOI stimulation of 5-HT2A receptors in A1A1v cells. These results suggest that the limited reduction in TGase2 protein with the siRNA treatment caused the less robust effect of TGase siRNA on DOI-induced Rac1 transamidation and activity compared to the cystamine rather than the increase in TGase1 protein.
In the present study, we demonstrated for the first time that Cdc42 is transamidated and activated following stimulation with DOI. First using A1A1v cells, we found that Cdc42 is transamidated and activated in a more delayed time course than Rac1 following treatment with DOI. Cdc42 transamidation and activation in A1A1v cells was significantly increased at two hours and 30 min after DOI treatment, respectively. It is unclear why there is a discordant time course for the effects of transamidation and activation, possibly due to the differences in the sensitivity of each assay or to additional mechanisms beyond transamidation playing a role in the activation of Cdc42. However in primary cortical cell cultures, both C. Q61N Rac1 is constitutively activated independent of DOI stimulation. PAK1 pull-down and detection of Rac1 on immunoblots demonstrate high constitutive activity for Q61N Rac1 mutants with and without DOI stimulation. Higher exposure demonstrates that activity of both wild-type and Q74N Rac1 mutants are stimulated with DOI. The immunoblot for Rac1 verifies transfection of the Rac1 constructs in cell lysates used for PAK1 pull-down. The experiment was repeated three times with similar results. We did not quantitate the blots for these experiments because the extremely large differences in the intensity of the bands are outside of the linear range of the assay. transamidation and activation of Cdc42 occurred rapidly, 15 min after DOI treatment.
We identified Q61 as the site on Rac1 that is transamidated; we found that the Rac1 Q61N mutant cannot be transamidated following 5-HT2A/2C receptor stimulation and is constitutively active. Previous studies found that transamidation or deamidation of Rac1 and Cdc42 at Q61 and RhoA at Q63 could inhibit both intrinsic and GAP-catalyzed hydrolysis of those GTPases, thereby rendering them constitutively active Schmidt et al., 1999; Flatau et al., 2000) . Together, these results suggest that transamidation of Rac1 at Q61 inhibits GTP hydrolysis of Rac1, thereby inhibiting Rac1 inactivation. Although further studies are needed to confirm that Rac1 and Cdc42 are indeed the TGase substrates mediating the increase in dendritic spine size, the Q61 A. F-actin in dendritic spines is labeled with phalloidin in primary cortical cultures treated with vehicle (Veh) and Veh, Veh and DOI, cystamine (Cys) and Veh, or Cys and DOI. Scale bar represents 5 mm.
B. DOI causes an increase in dendritic spine area after 30min treatment. Bars represent absolute value of dendritic spine area. Each dendrite had 11-41 dendritic spines, 8e10 dendrites (from 5 to 10 neurons/group, n ¼ 39 neurons) were measured for each treatment, resulting in 150e238 dendritic spines/treatment group for a total of 1007 dendritic spines measured. Log transformation was performed on original data to achieved normality. One-way repeated measures ANOVA suggests a significant difference between five treatment groups [F (4,34) ¼ 9.342, p < 0.001]. Newman-Keuls multiple comparison test indicates * p 0.001 compared with vehicle treatment group, and groups treated with DOI for 5min, 15min and 60min. C. Cystamine inhibits the DOI-induced dendritic spine enlargement. Bars represent absolute value of dendritic spine area. The number of spines measured in each group was 154 for vehicle, vehicle treated, 223 for vehicle, DOI treated, 122 for cystamine, vehicle treated and 164 for cystamine, DOI treated cells. Since log transformation did not result in a normal distribution of the data, analysis was performed on the original data using a non-parametric test. Kruskal-Wallis one-way ANOVA on Ranks indicates a significant difference between four treatment groups (p < 0.001, n ¼ 21 neurons). Post hoc Dunn's test suggests * p < 0.05 compared with vehicle-vehicle treatment; #p < 0.05 compared with vehicle-DOI treatment. D. DOI and cystamine have no significant effects on dendritic spine density. Bars represent absolute value of dendritic spine density. Log transformation was performed on original data to achieved normality. Two-way ANOVA test indicates that neither cystamine nor DOI has a significant effect on dendritic spine density. mutant constructs cannot be used to address this issue. Since the Q61Rac1 mutant is constitutively active, it unfortunately cannot be used to prevent Rac1 activation via transamidation and thereby assess the effects on functional outcomes such as dendritic spine morphology.
Several studies indicate that stimulation of Gaq/11-coupled receptors, such as bradykinin or endothelin-1 receptor, can cause small G protein activation (van Leeuwen et al., 1999; Clerk et al., 2001) . However, the underlying mechanisms still remain unclear. Our previous study indicated that 5-HT2A receptor-coupled PLC activation, as demonstrated by the PLC inhibitor U73122, and the subsequent increase in intracellular Ca 2þ , as demonstrated by chelation, are necessary for TGase-catalyzed Rac1 transamidation and activation (Dai et al., 2011) . Furthermore, an increase in intracellular Ca 2þ induced by the calcium ionophore ionomycin, is sufficient to cause Rac1 transamidation and activation in A1A1 cells, suggesting that receptor systems that increase in intracellular Ca 2þ may activate TGases to induce monoaminylation (Dai et al., 2011) . In present study, we extended these findings to 5-HT2C receptors and another family of Gaq/11-protein-coupled receptors, muscarinic acetylcholine receptors. Pretreatment with either the 5-HT2A or 5-HT2C receptor selective antagonist blocked the DOIinduced increase in Rac1 transamidation. These results suggest that both 5-HT2A and 5-HT2C receptors are able to cause an increase in Rac1 transamidation and that both receptors are necessary for the full effect of DOI on transamidation. In fact, pretreatment with a selective antagonist alone had a significant effect on Rac1 transamidation (main effect for pretreatment, p < 0.01), although there was no significant difference between the vehicle/vehicle and vehicle/MDL100907 or vehicle/SB242084 treated groups. Further studies are needed to determine if there is a constitutive effect of 5-HT2A or 5-HT2C receptor signaling on Rac1 activity. We found that stimulation of muscarinic receptors with carbachol increased the transamidation and activity of Rac1, both of which were suppressed by the TGase inhibitor cystamine. Furthermore, stimulation of NMDA receptors increased TGasecatalyzed activation of Rac1. Our results suggest that TGasemediated monoaminylation of small G proteins can serve as a common mechanism underlying the Gaq/11-coupled and ligand gated ion channel receptor-induced small G protein activation.
NMDA receptor stimulation resulted in TGase-dependent activation of Rac1 suggesting that transamidation of small G proteins could play a role in NMDA-dependent long term potentiation and synaptic plasticity. NMDA receptors are involved in the induction of synaptic plasticity and an increase in dendritic spine volume is a "morphological correlate of plasticity" (Collingridge et al., 1983; Nicoll and Roche, 2013) . Persistent activation of the Rho family of small G-proteins is necessary for synaptic plasticity (Murakoshi et al., 2011) . The link between NMDA receptor-stimulated increases in intracellular Ca 2þ and the persistent activation of Rho family G-proteins is unclear but our results suggest that it could involve TGase-catalyzed transamidation of the Rho G-proteins. Numerous studies have shown that Gaq/11-coupled receptors, such as the 5-HT2A receptor, metabotropic glutamate receptor 5 and muscarinic receptors, as well as PLC, Ca 2þ and calmodulin are upstream regulators of synaptogenesis and dendritic spines (Wess, 2004; Spires et al., 2005; Horne and Dell'Acqua, 2007; Wijetunge et al., 2008; Yamasaki et al., 2010; Sch€ atzle et al., 2011) . However, little was known about the signaling molecules coordinating these mechanisms. Our results suggest that 5-HT2A/2C receptor signaling pathways regulate dendritic spine morphology in rat cortical neurons via a TGase-mediated mechanism, likely monoaminylation of small G proteins. Furthermore, the results point to a possible role for TGase-mediated transamidation as a common down-stream signaling pathway for several receptor systems, most importantly NMDA receptors, in the regulation of dendritic spines. In conclusion, we report a novel receptor signaling pathway in the regulation of dendritic spines, thus providing further insight into neuropsychiatric and neurological disorders in which those receptors and dendritic spines are involved.
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